ReNeuron Group PLC (LON:RENE) has announced the appointment of Dr Richard Beckman as chief medical officer, to lead the company’s clinical and medical affairs team based in its recently established US office in Boston.
The AIM-listed firm said Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity.
WATCH: Reneuron’s Michael Hunt updates on product development
The cell-based therapeutics specialist said Beckman brings to ReNeuron more than 25 years of executive and consultancy experience in drug and device development.
Prior to joining ReNeuron, he was the chief medical officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech.
He also had leadership roles at Alcon, Lux Bio, Becton Dickinson and Co (NYSE:BDX) and Allergan PLC (NYSE:AGN).
Olav Hellebø, chief executive officer at ReNeuron, said: "His many years’ experience in medical practice and industry in the US will be invaluable to us as we build out our Boston team and increase our clinical activities in the US.”